Udo Holtick

4.8k total citations
87 papers, 1.9k citations indexed

About

Udo Holtick is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Udo Holtick has authored 87 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 34 papers in Hematology and 21 papers in Immunology. Recurrent topics in Udo Holtick's work include Hematopoietic Stem Cell Transplantation (29 papers), CAR-T cell therapy research (18 papers) and Acute Myeloid Leukemia Research (9 papers). Udo Holtick is often cited by papers focused on Hematopoietic Stem Cell Transplantation (29 papers), CAR-T cell therapy research (18 papers) and Acute Myeloid Leukemia Research (9 papers). Udo Holtick collaborates with scholars based in Germany, United States and United Kingdom. Udo Holtick's co-authors include Christof Scheid, Sebastian Theurich, Michael von Bergwelt‐Baildon, Alexander Shimabukuro‐Vornhagen, Anne M. Dickinson, Catharien M. U. Hilkens, Xiaonong Wang, Matthew Collin, Michael Hallek and Muzlifah Haniffa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Udo Holtick

83 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Udo Holtick Germany	25	728	631	546	337	326	87	1.9k
Tohru Inaba Japan	24	463 0.6×	392 0.6×	758 1.4×	402 1.2×	342 1.0×	117	1.8k
Paul G. Schlegel Germany	23	600 0.8×	480 0.8×	490 0.9×	435 1.3×	170 0.5×	56	1.8k
J.W. Gratama Netherlands	21	528 0.7×	503 0.8×	440 0.8×	405 1.2×	162 0.5×	44	1.7k
Raewyn Broady Canada	21	552 0.8×	1.0k 1.6×	402 0.7×	213 0.6×	155 0.5×	62	1.8k
Fen Huang China	26	566 0.8×	431 0.7×	1.2k 2.2×	340 1.0×	169 0.5×	155	2.2k
Omar Perbellini Italy	22	427 0.6×	922 1.5×	291 0.5×	327 1.0×	207 0.6×	50	1.9k
Noemí Puig Spain	22	532 0.7×	399 0.6×	836 1.5×	777 2.3×	393 1.2×	111	1.8k
Önder Alpdoğan United States	27	708 1.0×	1.8k 2.9×	1.2k 2.2×	391 1.2×	226 0.7×	112	2.9k
Cecilia C.S. Yeung United States	18	1.3k 1.8×	365 0.6×	379 0.7×	392 1.2×	222 0.7×	81	2.0k
Marta Coscia Italy	27	884 1.2×	1.3k 2.1×	362 0.7×	513 1.5×	342 1.0×	80	2.2k

Countries citing papers authored by Udo Holtick

Since Specialization

Citations

This map shows the geographic impact of Udo Holtick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Udo Holtick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Udo Holtick more than expected).

Fields of papers citing papers by Udo Holtick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Udo Holtick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Udo Holtick. The network helps show where Udo Holtick may publish in the future.

Co-authorship network of co-authors of Udo Holtick

This figure shows the co-authorship network connecting the top 25 collaborators of Udo Holtick. A scholar is included among the top collaborators of Udo Holtick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Udo Holtick. Udo Holtick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kobbe, Guido, Tobias A.W. Holderried, Martina Crysandt, et al.. (2025). Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis. Blood Advances. 9(6). 1370–1375. 2 indexed citations

Holtick, Udo, Hyatt Balke‐Want, Sandra Sauer, et al.. (2025). Sequential BCMA CAR T-cell therapy in refractory multiple myeloma. Blood Advances. 9(18). 4624–4630.

Müller, Susanne, Gabriele D. Maurer, Jessica Hartmann, et al.. (2025). CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts. EMBO Molecular Medicine. 17(2). 211–218. 5 indexed citations

Kutsch, Nadine, Philipp Gödel, Conrad‐Amadeus Voltin, et al.. (2024). Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation. European Journal Of Haematology. 112(6). 984–987. 1 indexed citations

Weaver, Alice N., Wade T. Iams, Jong Chul Park, et al.. (2024). Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular Carcinogenesis. 63(8). 1421–1428. 2 indexed citations

Gertz, Roman Johannes, Lenhard Pennig, Udo Holtick, et al.. (2024). Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment. Journal of Clinical Medicine. 13(1). 284–284. 9 indexed citations

Pralong, Anne, et al.. (2024). The life threat in hematopoietic allogeneic stem cell transplantation - an interview and focus group study on health care professionals’ perspectives. Annals of Hematology. 103(10). 4251–4259.

Holtick, Udo, et al.. (2024). Clinical and Economic Burden Associated With Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation in Germany. Transplantation Proceedings. 56(1). 191–200. 1 indexed citations

Eberhardt, Kirsten Alexandra, Elena Knops, Eva Heger, et al.. (2023). CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplantation. 58(6). 639–646. 13 indexed citations

10.

Schroeder, Thomas, Matthias Stelljes, Maximilian Christopeit, et al.. (2023). Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica. 108(11). 3001–3010. 10 indexed citations

11.

Kaddu‐Mulindwa, Dominic, Philipp Gödel, Nadine Kutsch, et al.. (2022). Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 22(7). e498–e506. 1 indexed citations

12.

Gehlsen, Uta, Michael E. Stern, Jeremy Franklin, et al.. (2022). Desiccating Stress Significantly Increases the Risk for Chronic Ocular Graft-versus-Host-Disease. Transplantation and Cellular Therapy. 28(11). 782.e1–782.e7. 6 indexed citations

13.

Dertschnig, Simone, P Gergely, Jürgen Finke, et al.. (2022). Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy. Transplantation and Cellular Therapy. 29(1). 41.e1–41.e9. 10 indexed citations

14.

Ram, Ron, Christof Scheid, Odelia Amit, et al.. (2019). Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 104(9). 1798–1803. 6 indexed citations

15.

Lock, Dominik, Nadine Mockel-Tenbrinck, Daniela Mauer, et al.. (2017). Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. Human Gene Therapy. 28(10). 914–925. 85 indexed citations

16.

Holtick, Udo, Marco Herling, Natali Pflug, et al.. (2016). Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. Annals of Hematology. 96(3). 479–487. 18 indexed citations

17.

Chakupurakal, Geothy, Petra Langerbeins, Joanna Schiller, et al.. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality—a single institution experience. Annals of Hematology. 94(10). 1717–1725. 2 indexed citations

18.

Theurich, Sebastian, Geothy Chakupurakal, Alexander Shimabukuro‐Vornhagen, et al.. (2013). Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis—A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 88(1). 178–186. 28 indexed citations

19.

Cremer, Birgit, Brenda M. Sandmaier, Wolfgang Bethge, et al.. (2011). Reduced-Intensity Conditioning in Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Historical Perspective. Onkologie. 34(12). 710–715. 5 indexed citations

20.

Holtick, Udo, Martina Vockerodt, Nils Schoof, et al.. (2005). STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia. 19(6). 936–944. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact